The newer agent faricimab is a bispecific antibody built on a human IgG1 framework developed to simultaneously inhibit VEGF-A and Ang-2, with the goal of promoting vascular stability in retinal vascular diseases such as AMD and diabetic retinopathy [87,88]. Here, ANGPT2 is linked to age-related macular degeneration.